Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
50.77
+2.51 (5.20%)
At close: Oct 9, 2025, 4:00 PM EDT
50.93
+0.16 (0.31%)
After-hours: Oct 9, 2025, 7:59 PM EDT
Avidity Biosciences Revenue
Avidity Biosciences had revenue of $3.85M in the quarter ending June 30, 2025, with 88.12% growth. This brings the company's revenue in the last twelve months to $10.73M, up 1.23% year-over-year. In the year 2024, Avidity Biosciences had annual revenue of $10.90M with 13.99% growth.
Revenue (ttm)
$10.73M
Revenue Growth
+1.23%
P/S Ratio
679.77
Revenue / Employee
$27,440
Employees
391
Market Cap
7.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.90M | 1.34M | 13.99% |
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RNA News
- 3 days ago - Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - PRNewsWire
- 24 days ago - Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 4 weeks ago - Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha
- 4 weeks ago - Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 4 weeks ago - Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript) - Seeking Alpha
- 4 weeks ago - Avidity Biosciences Announces Proposed Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 - PRNewsWire